Ironwood Pharmaceuticals (IRWD)
NASDAQ:IRWD
Want to see IRWD full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.36Last Year’s EPS
0.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a predominantly positive outlook driven by strong LINZESS Q1 performance (97% YoY net sales growth), robust profitability (GAAP net income $40.8M; adjusted EBITDA $76.7M), healthy cash on hand, and clear progress toward initiating the STARS‑2 confirmatory trial for apraglutide with supportive efficacy and safety data. Key near‑term risks include the June convertible note maturity (reliance on receivable collection), anticipated R&D spend and enrollment risk for STARS‑2, and potential moderation of prescription growth later in 2026 (notably in Medicaid). Overall, the positive financial momentum and clinical progress outweigh the manageable execution and timing risks noted.Company Guidance
LINZESS Q1 U.S. Net Sales Surge
LINZESS U.S. net sales of $272.5M in Q1 2026, a 97% year‑over‑year increase, driven primarily by improved net price and 5% prescription demand growth; company expects to return LINZESS to blockbuster status and set a new all‑time high for annual U.S. net sales in 2026. FDA accepted sNDA for functional constipation in children 2–5 with a PDUFA date of May 24, 2026.
Strong GAAP and Non‑GAAP Profitability
Q1 GAAP net income of $40.8M and adjusted EBITDA of $76.7M; company reiterated 2026 adjusted EBITDA guidance of >$300M and Ironwood revenue guidance of $450M–$475M.
Balance Sheet and Liquidity Position
Cash and cash equivalents of $220.5M and $105.8M in accounts receivable expected to be collected prior to June 15 convertible note maturity; plan to repay the 2026 convertible note in cash and target year‑end total debt of ~ $300M (less than 1x expected 2026 adjusted EBITDA).
Brand Collaboration Revenue Expansion
Recognized $104.2M in U.S. brand collaboration revenue in Q1 2026, a 169% increase versus $38.8M in Q1 2025.
Apraglutide Clinical Progress and Market Opportunity
Advanced STARS‑2 confirmatory Phase III program (site feasibility complete; on track for site initiation in Q2 2026). Prior STARS Phase III showed ~2x relative parenteral support (PS) volume reduction at 24 weeks versus placebo; STARS Extend reported ~20% of patients achieving enteral autonomy (as of Jan 2025). Pooled long‑term safety data consistent with prior studies. Estimated SBS‑IF population ~18,000 (U.S., Europe, Japan) with >8,000 U.S. patients on PS ≥3 days/week; U.S. TAM >$4B and apraglutide peak U.S. net sales potential >$700M per company estimates.
Improved Gross‑to‑Net Dynamics
Net price benefited from elimination of inflationary rebates across channels (including Medicaid) and favorable timing of gross‑to‑net rebate reserves; company expects reduced sequential quarterly variability in LINZESS U.S. net sales in 2026 versus 2025.
IRWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IRWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $4.83 | $4.17 | -13.66% |
Feb 25, 2026 | $3.79 | $3.36 | -11.35% |
Nov 10, 2025 | $1.92 | $2.53 | +31.77% |
Aug 07, 2025 | $0.81 | $0.88 | +9.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ironwood Pharmaceuticals (IRWD) report earnings?
Ironwood Pharmaceuticals (IRWD) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Ironwood Pharmaceuticals (IRWD) earnings time?
Ironwood Pharmaceuticals (IRWD) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IRWD EPS forecast?
IRWD EPS forecast for the fiscal quarter 2026 (Q2) is 0.36.